



REMARKABLE SCIENCE. ENDURING PERFORMANCE.™

Revance Therapeutics
Investor Relations Department
7555 Gateway Boulevard
Newark, CA 94560
United States

Visit IR website
Sign-up for Email alerts

NASDAQ: RVNC


Last Trade:	30.85
Trade Time:	1:14 PM ET Feb 22, 2018
Change:	0.50 (+1.647%)
Day Range	30.40 - 32.30
52-Week Range	18.00 - 37.45
Volume	135,854

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, including muscle movement disorders and pain. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis with the potential to be the first long-acting neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide technology designed to create novel, differentiated therapies. The company has a comp... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Feb 14, 2018*
[Revance to Participate in the RBC Capital Markets 2018 Global Healthcare Conference](#)
- Feb 1, 2018*
[Pivotal SAKURA Phase 3 Clinical Data to be Presented at IMCAS World Congress 2018](#)
- Jan 8, 2018*
[Revance Announces Interim Phase 2a Results for RT002 in Treating Plantar Fasciitis](#)
- Jan 4, 2018*
[Revance Provides Update on Anticipated Clinical Milestones and Financial Outlook for 2018](#)
- Dec 11, 2017*
[Revance Announces Closing of Public Offering of Common Stock](#)

Financials [\[View all \]](#)

- [Third Quarter Financial Results](#)
- Feb 28, 2017*
[Annual Report \(10-K\)](#)
- Mar 24, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 3, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 4, 2017*
[Quarterly Report \(10-Q\)](#)
- May 9, 2017*
[Quarterly Report \(10-Q\)](#)